Seagen Inc.
- Country
- ๐บ๐ธUnited States
- Ownership
- Public, Subsidiary
- Established
- 1998-01-01
- Employees
- 3.2K
- Market Cap
- -
- Website
- http://www.seagen.com
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
- Conditions
- Precursor B-cell Lymphoblastic Leukemia-LymphomaBurkitt Lymphoma
- Interventions
- First Posted Date
- 2013-02-07
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 92
- Registration Number
- NCT01786096
- Locations
- ๐บ๐ธ
Boston Children's Hospital, Boston, Massachusetts, United States
๐บ๐ธAll Children's Hospital, Saint Petersburg, Florida, United States
๐บ๐ธDana Farber Cancer Institute, Boston, Massachusetts, United States
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas
- Conditions
- T-Cell LymphomaAnaplastic Large-Cell LymphomaNon-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2013-01-28
- Last Posted Date
- 2021-11-30
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 452
- Registration Number
- NCT01777152
- Locations
- ๐บ๐ธ
Weill Cornell Medical College, New York, New York, United States
๐บ๐ธMemorial Sloan Kettering Cancer Center - Basking Ridge, Basking Ridge, New Jersey, United States
๐ฎ๐ฑTel Aviv Sourasky Medical Center, Tel Aviv, Israel
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
- Conditions
- Hodgkin DiseasePeripheral T Cell Lymphoma
- Interventions
- First Posted Date
- 2012-10-30
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 131
- Registration Number
- NCT01716806
- Locations
- ๐บ๐ธ
Wenatchee Valley Medical Center, Wenatchee, Washington, United States
๐บ๐ธJames Cancer Hospital / Ohio State University, Columbus, Ohio, United States
๐บ๐ธSwedish Cancer Institute, Seattle, Washington, United States
A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
- First Posted Date
- 2012-09-03
- Last Posted Date
- 2014-01-28
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT01677390
- Locations
- ๐บ๐ธ
Stanford Cancer Center, Stanford, California, United States
๐บ๐ธRocky Mountain Cancer Centers - Midtown, Denver, Colorado, United States
๐บ๐ธMemorial Sloan Kettering Cancer Center, New York, New York, United States
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
- Conditions
- Acute Myeloid LeukemiaAcute Lymphoid LeukemiaAnemia, Refractory, With Excess of BlastsSolid Tumors
- Interventions
- First Posted Date
- 2011-10-28
- Last Posted Date
- 2016-03-04
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT01461538
- Locations
- ๐บ๐ธ
Mayo Clinic Cancer Center, Jacksonville, Florida, United States
๐บ๐ธOcala Oncology Center, Ocala, Florida, United States
๐บ๐ธNorthwest Cancer Specialists, P.C., Tulatin, Oregon, United States
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma
- Conditions
- Lymphoma, Non-HodgkinLymphoma, B-CellLymphoma, Large B-Cell, DiffuseLymphoma, T-Cell
- Interventions
- First Posted Date
- 2011-08-23
- Last Posted Date
- 2016-11-28
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 176
- Registration Number
- NCT01421667
- Locations
- ๐บ๐ธ
Northwestern University, Chicago, Illinois, United States
๐บ๐ธUniversity of Chicago, Chicago, Illinois, United States
๐บ๐ธStanford Cancer Center, Stanford, California, United States
A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms
- Conditions
- Lymphoma, Large-Cell, AnaplasticLymphoma, NK-cellLymphoma, T-cell
- Interventions
- First Posted Date
- 2011-03-07
- Last Posted Date
- 2017-06-28
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT01309789
- Locations
- ๐บ๐ธ
UAB Comprehensive Cancer Center, Birmingham, Alabama, United States
๐บ๐ธCity of Hope National Medical Center, Duarte, California, United States
๐บ๐ธStanford Cancer Center, Stanford, California, United States
A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001
- Conditions
- Lymphoma, Non-HodgkinDisease, HodgkinLymphoma, Large-Cell, AnaplasticLymphoma, T-Cell, Cutaneous
- First Posted Date
- 2010-09-08
- Last Posted Date
- 2020-09-21
- Lead Sponsor
- Seagen Inc.
- Registration Number
- NCT01196208
- Locations
- ๐บ๐ธ
MD Anderson Cancer Center / University of Texas, Houston, Texas, United States
๐ง๐ฌSpecializirana bolnica aktivno lechenie detsa ohcohematologichni zabolyavania Hematologichno, Sofia, Bulgaria
๐ต๐ฑCentrum Onkologii Institut im. Marii Sklodowskiej-Curie, Warsaw, Poland
A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma
- First Posted Date
- 2010-07-21
- Last Posted Date
- 2013-08-27
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT01166490
- Locations
- ๐บ๐ธ
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธUniversity of Chicago, Chicago, Illinois, United States
๐บ๐ธTexas Oncology - Tyler, Tyler, Texas, United States
A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)
- First Posted Date
- 2010-04-09
- Last Posted Date
- 2021-05-14
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 329
- Registration Number
- NCT01100502
- Locations
- ๐บ๐ธ
Cardinal Bernardin Cancer Center / Loyola University Medical Center, Maywood, Illinois, United States
๐บ๐ธCleveland Clinic, The, Cleveland, Ohio, United States
๐บ๐ธWestern Pennsylvania Cancer Institute, Pittsburgh, Pennsylvania, United States